# Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT07699185** · PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 336 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Cardonilizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** neoadjuvant chemoradiotherapy

## Key facts

- **NCT ID:** NCT07699185
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699185, "Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*